Table 2 Treatment outcomes for patients with EGFR exon 19 insertion mutations undergoing TKI therapy

P9

Female

LUAD

IV

I740_K745dup

Gefitinib

2

Erlotinib + Bevacuzumab

11

Osimertinib

1.4

P28

Male

LUAD

IV

I740_K745dup

Gefitinib

2.5

-

-

-

-

P17

Male

LUAD

IV

I740_K745dup

Gefitinib

5

-

-

-

-

P46

Male

LUAD

IV

I740_K745dup

Gefitinib

7

-

-

-

-

P16

Male

LUAD

IV

I740_K745dup

Icotinib

6

Afatinib

8

-

-

P50

Female

LUAD

IV

I740_K745dup

Icotinib

7

Icotinib + chemotherapy

6

Erlotinib + chemotherapy

12

P44

Female

LUAD

IV

I740_K745dup

Icotinib

10.6

-

-

-

-

P60

Male

LUAD

IV

I740_K745dup

Icotinib

11.2

-

-

-

-

P11

Female

LUAD

IV

I740_K745dup

Icotinib

14.6

-

-

-

-

P54

Female

LUAD

IV

I740_K745dup

Erlotinib

9.4

-

-

-

-

P39

Male

LUAD

Unknown

I740_K745dup

Afatinib

12.5

-

-

-

-

P68

Male

LUAD

IV

I740_K745dup

Osimertinib

7.4

-

-

-

-

P22

Female

LUAD

IV

I740_K745dup

Osimertinib + Bevacuzumab

7.8

P15

Female

LUAD

IV

I740_K745dup

Osimertinib + chemotherapy

10.6

-

-

-

-

P30

Male

LUAD

IV

K745_E746insVPVAIK

Gefitinib

5.6

-

-

-

-

P69

Male

LUAD

IV

K745_E746insVPVAIK

Icotinib

13

Osimertinib

5.5

-

-

P76

Male

LUAD

IV

K745_E746insVPVAIK

Erlotinib

36

-

-

-

-